Tryptase
TPSAB1proteinTryptase is a mast cell-derived serine protease that degrades endothelial extracellular matrix and contributes to endothelial erosion in Type 1 MI.
Pathway placement
Cascade stepEndothelial activation & erosion
Confidencemedium
RationaleMast cell serine protease; degrades endothelial matrix and promotes vasodilation; mechanistically implicated in erosion.
Also acts inCap degradation / rupture
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000172236
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I60
C — confounder / Type-II84
A — assay feasibility68
E — evidence strength32
T1DI (composite)8
Specificity differential (R−C)-24.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion.Coronary artery disease · 2006 · PMID 17047445 · doi
- Serum tryptase levels in acute coronary syndromes.International journal of cardiology · 2005 · PMID 16168805 · doi
Clinical trials(1)
- Evaluation of Tryptase as a Biomarker of Coronary Heart DiseaseNCT01618279 · COMPLETED